RT Journal Article
SR Electronic
T1 Detection of Numerical Abnormalities of Chromosome 9 and p16/CDKN2A Gene Alterations in Ovarian Cancer with Fish Analysis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5309
OP 5313
VO 32
IS 12
A1 ARAVIDIS, CHRISTOS
A1 PANANI, ANNA D.
A1 KOSMAIDOU, ZOI
A1 THOMAKOS, NIKOLAOS
A1 RODOLAKIS, ALEXANDROS
A1 ANTSAKLIS, ARISTEIDIS
YR 2012
UL http://ar.iiarjournals.org/content/32/12/5309.abstract
AB Background: The molecular events leading to the development of ovarian cancer are not well-established. Defects of the retinoblastoma protein (pRb)/cyclin-D1/p16 pathway have been shown to play a critical role in the development of human malignancies. In particular, the p16/cyclin-dependent kinase inhibitor 2A (CDKN2A) gene located on chromosomal region 9p21 frequently is altered in several types of cancer. Materials and Methods: To investigate both the presence of numerical abnormalities of chromosome 9 and p16 gene alterations in ovarian cancer, we studied 28 cases by the fluorescence in situ hybridization (FISH) technique using a DNA p16 probe and an a-satellite probe specific for chromosome 9. Results: Numerical abnormalities of chromosome 9 were found in all studied cases. Polysomy 9 was detected in 10 cases while monosomy 9 in seven cases. In 11 cases, there were two cell populations, one with polysomy 9 and the other with monosomy 9. In all cases, the p16 gene deletion was observed. Among them, 25 cases presented deletion of p16 gene in 21.43%-86.3% of the examined cells. Three cases carried deletion of the p16 gene in a lower proportion (12.04%-19.49%). In five cases with p16 gene deletion, homozygous deletion was detected. Conclusion: Numerical aberrations of chromosome 9 and p16 gene deletion are common findings in ovarian cancer. Data suggest that the p16 gene, located in the short arms of chromosome 9, may play a role in ovarian carcinogenesis. In addition, polysomy 9 could lead to activation of a number of oncogenes, thus participating in the neoplastic process in the ovaries.